Peptides for Gut Health — The Complete Guide

VEGF Angiogenesis · FAK-Paxillin · Tight Junction Restoration · ENS Modulation

BPC-157 is the most extensively studied gut healing peptide available. Its primary mechanism in gastrointestinal tissue is VEGF-driven angiogenesis — stimulating new blood vessel formation in the gut wall's mucosal microvasculature. It activates the FAK-paxillin pathway to stimulate epithelial cell migration and tight junction restoration — the molecular zipper between adjacent epithelial cells that determines gut permeability. It upregulates growth hormone receptor expression in intestinal tissue, has documented cytoprotective effects against NSAIDs, alcohol, and corticosteroids, and modulates the enteric nervous system for improved gut motility. Oral BPC-157 is the preferred delivery route for gut applications — it delivers directly to the intestinal lumen and mucosal surface.

NF-κB Suppression · JAK-STAT Inhibition · Cytokine Reduction

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH carrying its primary anti-inflammatory biological activity. KPV acts on intestinal epithelial cells and lamina propria immune cells to reduce NF-κB nuclear translocation — the master transcription factor driving pro-inflammatory cytokine production in the gut wall. Its published effects include reduction of IL-6, IL-8, TNF-alpha, and IL-1beta — the primary cytokine signature of IBD, Crohn's, and ulcerative colitis. KPV also directly inhibits the JAK-STAT pathway that IBD biologics target. At VitalRx, KPV is available exclusively in combination with BPC-157 — as oral capsules for intestinal inflammation, and as the BPC-157/TB500/KPV injectable blend for significant structural mucosal damage.

T-Regulatory Cell Maturation · GALT Homeostasis · Th1/Th17 Balance

The gut contains approximately 70% of the body's immune cells. This immune system must perform two simultaneous and opposing functions: tolerance of commensal organisms and defense against pathogens. The failure mode in IBD and chronic gut inflammation is typically pathological immune activation against commensal organisms or dietary antigens. Thymosin Alpha-1 promotes T-regulatory cell maturation and function — the immune cell population most responsible for maintaining gut immune tolerance. It reduces pathological Th1/Th17 activation that drives IBD-type intestinal inflammation while preserving immune competence needed for pathogen defense.

Gene Expression Modulation · NF-κB Suppression · Submucosal ECM Repair

GHK-Cu modulates the expression of over 4,000 genes — including significant upregulation of anti-inflammatory pathways and downregulation of NF-κB-driven pro-inflammatory signaling. For gut health, this provides a broad reduction in the inflammatory background that sustains chronic gut inflammation, complementing KPV's more targeted intestinal cytokine suppression. GHK-Cu also promotes VEGF-driven vascularization and ECM remodeling — supporting organized repair of the submucosa and connective tissue architecture that chronic inflammation disrupts. It is the systemic anti-inflammatory and structural foundation layer of gut health protocols.

GABAergic Anxiolysis · HPA Axis · CRF Suppression · Serotonin Stabilization

The gut-brain axis is a bidirectional communication network connecting the enteric nervous system with the CNS via the vagus nerve, HPA axis, and systemic immune signaling. Chronic stress activates the HPA axis, elevates cortisol, and drives CRF signaling in the gut — producing visceral hypersensitivity, altered motility, and mucosal barrier disruption that are the pathological basis of IBS and stress-driven functional gut disorders. Selank reduces HPA axis hyperactivation through GABAergic anxiolysis and serotonin stabilization — normalizing the central stress response generating peripheral gut pathology. For patients with IBS-pattern symptoms that worsen under stress, Selank represents a fundamentally more upstream intervention than gut-targeted compounds alone.

Primary Gut Repair Compound

• Oral delivery — BPC-157 was originally isolated from gastric juice, making oral the most physiologically natural gut route
• Delivers directly to the intestinal lumen and mucosal surface for maximum local gut wall contact
• VEGF upregulation restores the mucosal microvasculature that sustains gut lining integrity
• FAK-paxillin activation drives epithelial cell migration and tight junction restoration — directly addresses leaky gut
• Cytoprotective against NSAIDs, alcohol, corticosteroids, and other common mucosal insults
• Modulates enteric nervous system activity — improves dysmotility and gut motility patterns

• BPC-157 500mcg: full mucosal repair mechanism — angiogenesis, epithelial migration, tight junction restoration
• KPV 500mcg: NF-κB suppression — reduces IL-6, IL-8, TNF-alpha, IL-1beta in intestinal tissue
• KPV inhibits JAK-STAT pathway — parallel mechanism to IBD biologics in a single oral capsule
• Dual mechanism: BPC-157 drives repair signaling; KPV removes the inflammation blocking that repair
• The most clinically appropriate oral gut compound for patients with active gut inflammation alongside barrier dysfunction
• Oral delivery maintains direct mucosal contact for both BPC-157 and KPV in the intestinal lumen

• Systemic delivery — reaches upper GI tract (stomach, esophagus, duodenum) with higher bioavailability than oral
• Cytoprotective for gastric mucosa — most appropriate when gastric ulcer, GERD, or upper GI involvement is present
• Supports enteric nervous system modulation systemically alongside local gut effects
• Can be combined with oral BPC-157 for dual-route coverage — oral for lower GI, injectable for upper GI and systemic
• VEGF and FAK-paxillin mechanisms identical to oral — systemic distribution rather than local gut delivery
• Neuroprotective effects on dopaminergic pathways — relevant for the gut-brain axis

• BPC-157 3mg/mL: VEGF angiogenesis, tight junction repair, GH receptor upregulation
• TB500 (Thymosin Beta-4 fragment) 3mg/mL: actin-mediated epithelial and immune cell migration to injury sites
• KPV 3mg/mL: intestinal NF-κB suppression and inflammatory cytokine reduction
• TB500 addition addresses the cell migration layer that oral BPC-157/KPV does not directly target
• Three mechanisms in a single injection — the most comprehensive gut repair injectable in the VitalRx catalog
• Appropriate when mucosal damage is significant enough to require active cell recruitment alongside repair signaling

• Promotes T-regulatory cell maturation — the immune population responsible for gut immune tolerance
• Reduces pathological Th1/Th17 immune activation driving IBD-type intestinal inflammation
• Preserves immune competence while normalizing pathological immune activation — not a broad immunosuppressant
• Enhances innate immune signaling — relevant for patients with secondary infection vulnerability
• Addresses the immunological root of gut inflammation rather than its downstream cytokine expression
• Published data in IBD models, immune dysregulation, and systemic inflammatory conditions

• Modulates over 4,000 genes — significant NF-κB anti-inflammatory effect reducing the systemic inflammatory background
• Promotes VEGF-driven vascularization for submucosal ECM repair in chronically inflamed gut tissue
• Supports organized collagen synthesis and connective tissue remodeling in the gut wall
• Reduces the chronic systemic inflammation that perpetuates gut pathology from outside the gut itself
• Complements KPV's targeted intestinal cytokine suppression with broader gene-level anti-inflammatory activity
• Relevant for patients with gut inflammation in the context of systemic inflammatory burden

• Selank: reduces HPA axis hyperactivation that drives CRF-mediated gut motility disruption and visceral hypersensitivity
• GABAergic anxiolysis normalizes the central stress response generating peripheral gut-brain axis pathology
• Serotonin system stabilization — relevant given that over 90% of serotonin is produced in the gut
• Addresses the neurological and psychological driver of functional gut disorders at its source
• Intranasal delivery — rapid CNS uptake for gut-brain axis effect
• Semax component provides concurrent neurotrophic and cognitive benefits

Patients with increased intestinal permeability — food sensitivities, systemic inflammation, skin reactions — where tight junction restoration and mucosal angiogenesis are the primary repair targets.

Patients with diagnosed or suspected IBD presenting with active inflammation, mucosal damage, and immune dysregulation — where the protocol must simultaneously address repair, inflammation control, and immune homeostasis.

Patients with IBS-pattern symptoms — cramping, bloating, alternating bowel habits, visceral hypersensitivity — where no structural pathology has been identified but functional gut-brain axis disruption is the primary driver.

Patients recovering from significant gut disruption — antibiotic-associated dysbiosis, post-surgical gut healing, or chemotherapy-related mucositis — where rapid restoration of mucosal integrity and immune competence are the primary goals.

Days 1–14

Cytoprotection and Acute Symptom Response

BPC-157's cytoprotective effects begin within the first days of oral administration — patients with active gut discomfort, cramping, or pain often report reduced symptom severity within the first 1–2 weeks. Selank's gut-brain axis effects on IBS-pattern symptoms are typically apparent within the first 1–2 weeks. KPV's anti-inflammatory cytokine suppression begins within days — patients with IBD-pattern inflammation often report reduced urgency and discomfort within the first 2 weeks.

Weeks 2–6

Mucosal Repair and Barrier Restoration

BPC-157's VEGF angiogenesis and tight junction repair effects accumulate as the mucosal microvasculature rebuilds and epithelial integrity improves. Patients with leaky gut or food sensitivity patterns often notice reduced reactivity to previously problematic foods by weeks 3–6. Thymosin Alpha-1's T-regulatory effects begin establishing improved gut immune tolerance — reduced flare frequency in IBD patients is often reported within 4–6 weeks.

Months 2–4 and Beyond

Immune Homeostasis and Sustained Repair

The most significant and durable gut improvements — particularly in IBD, chronic leaky gut, and immune-driven gut pathology — develop over months of consistent protocol adherence. Patients often describe the improvement as gradual and cumulative: fewer flares, more resilience to dietary triggers, reduced need for symptomatic medications, and a progressive normalization of gut function that compounds over time.

BPC-157 Oral Capsules — 500mcg, 20ct

Primary gut lining repair. Oral delivery for direct mucosal contact.

BPC-157 / KPV Oral — 500mcg + 500mcg, 20ct

Dual oral gut stack — BPC-157 repair + KPV inflammation suppression.

BPC-157 Injectable — 3mg/mL, 5mL

Systemic BPC-157 for upper GI and whole-body cytoprotection.

BPC-157 / TB500 / KPV Injectable — 5mL

Three-mechanism gut repair stack for significant mucosal damage.

Thymosin Alpha-1 — 3mg/mL, 5mL

T-regulatory cell promotion for gut-immune tolerance. The immune layer of IBD protocols.

GHK-Cu Injectable — 10mg/mL, 5mL

Systemic NF-κB suppression and submucosal ECM remodeling.

Semax / Selank Nasal Spray

Selank GABAergic gut-brain axis normalization for IBS and stress-driven gut disorders.

Identify Your Gut Pattern

Is the primary issue barrier dysfunction and food sensitivities — suggesting BPC-157 oral? Active IBD inflammation — suggesting BPC-157/KPV with Thymosin Alpha-1? IBS with stress as a clear trigger — suggesting Selank? Or post-treatment gut recovery — suggesting BPC-157 with Thymosin Alpha-1 for immune reconstitution?

Complete Your Async Provider Consultation

Answer a brief health intake at your own pace — describe your gut symptoms, diagnosis history, current medications, and how long the condition has been present. A licensed provider reviews your submission and issues your prescription when clinically appropriate. Consultation included with every order.

Receive Your Order

Your prescription is filled by Optimal Balance Pharmacy and shipped via FedEx Standard Overnight. Syringes and alcohol swabs included with all injectable orders.

Build the Protocol Over Time

Most gut health protocols start with oral BPC-157 or BPC-157/KPV as the foundation and add immune and systemic layers as the initial repair compounds establish their effect. Expect meaningful improvement over weeks, with the most significant changes developing over 2–4 months.